Nouvelles études psychopharmacologiques sur la méthadone: Implications pour le traitement de la dépendance aux opiacés

Revue Medicale de la Suisse Romande

Volumn 120, Issue 2, 2000, Pages 111-116

  Eap, Chin B ^a,b  

^a Hopital de Cery   (Switzerland)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; BIOAVAILABILITY; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; HUMAN; METABOLISM; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; PSYCHOLOGICAL ASPECT;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0034137057     PISSN: 00353655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bertschy G.: Methadone maintenance treatment: an update. Eur. Arch. Psychiatry Clin. Neurosci., 245: 114-124, 1995.
2. Eap C.B., Déglon J.J., Baumann P.: Pharmacokinetics and pharmacogenetics of methadone: clinical-relevance. Heroin Addiction and Related Clinical Problems, 1: 19-34, 1999.
3. Dole V.P.: Implications of methadone maintenance for theories of narcotic addiction. JAMA, 260: 3025-3029, 1988.
4. Eap C.B., Finkbeiner T., Gastpar M., Scherbaum N., Powell K., Baumann P.: Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive, changes in methadone pharmacokinetics. Eur. J. Clin. Pharmacol., 50: 385-389, 1996.
5. Eap C.B., Bertschy G., Powell K., Baumann P.: Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J. Clin. Psychopharmacol., 17: 113-117, 1997.
6. Rendic S., Di Carlo F.J.: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews, 29: 413-580, 1997.
7. Borg L., Kreek-M.J.: Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1-positive and AIDS patients. Current Opinion in Psychiatry, 8: 199-202, 1995.
8. Eap C.B., Bertschy G., Finkbeiner T., Gastpar M., Scherbaum N., Baumann P.: High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry, 55: 89-90, 1998.
9. Payte J.T., Khuri E.T.: Principles of methadone dose determinations. In: U.S.Department of Health and Human Services, Ed. State Methadone Treatment Guidelines. Rockwall, Rockville, MD, 101-124, 1993.
10. Maxwell S., Shinderman M.: Optimizing response to methadone maintenance treatment: Use of higher dose methadone. J. Psychoactive Drugs, 1999.